HR 5416

Give Kids a Chance Act

Congress: 117 (2021–2023, Ended)
Chamber: House
Policy Area: Health
Introduced: Sep 29, 2021
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Sep 30, 2021)
Official Text: https://www.congress.gov/bill/117th-congress/house-bill/5416

Sponsor

Name: Rep. Butterfield, G. K. [D-NC-1]
Party: Democratic • **State:** NC • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Sep 29, 2021
Rep. Wild, Susan [D-PA-7]	D · PA		Sep 29, 2021
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Jan 12, 2022
Rep. Cohen, Steve [D-TN-9]	D · TN		Jan 19, 2022
Rep. Higgins, Brian [D-NY-26]	D · NY		Feb 1, 2022
Rep. Ross, Deborah K. [D-NC-2]	D · NC		Feb 3, 2022
Rep. O'Halleran, Tom [D-AZ-1]	D · AZ		Mar 7, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 30, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4215	Related bill	**May 12, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 6972	Related bill	**Mar 9, 2022:** Referred to the Subcommittee on Health.

Summary (as of Sep 29, 2021)

Give Kids a Chance Act

This bill authorizes the Food and Drug Administration (FDA) to take various actions regarding pediatric cancer treatments, such as requiring pediatric cancer trials involving a combination of drugs when an applicant seeks market approval for a new drug (or biological product).

For an application for market approval for a new adult cancer treatment drug, if the FDA determines that the drug in question is substantially relevant to the growth or progression of a pediatric cancer, the FDA may require a pediatric cancer investigation into that drug's active ingredient in combination with another active ingredient that has received market approval or an exemption for investigational use. Currently, the FDA may only require a pediatric cancer trial for the drug in the application.

Furthermore, when the FDA receives an application for an investigational use exemption for an adult cancer treatment drug, the FDA may require the applicant to conduct up to two preclinical studies to determine the relevance of the drug to pediatric cancer.

Actions Timeline

- **Sep 30, 2021:** Referred to the Subcommittee on Health.
- **Sep 29, 2021:** Introduced in House
- **Sep 29, 2021:** Referred to the House Committee on Energy and Commerce.

LegiList

CONGRESS, MADE CLEAR.

Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

legilist.com

Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

legilist.com/learn

Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

legilist.com/api

Public data belongs to the public. — legilist.com